ACHIEVE-4, the longest Phase 3 study of Lilly’s Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health

AF Screening May Flag Increased HF Risk

Graham Steell: Bedside Cardiology Before the ECG

Culture-Negative Endocarditis Shows Distinct Patterns

Adding Steroid Shows No Heart Benefit in Kawasaki Disease

Long-term antidepressant use may increase risk of sudden cardiac death

Stereotaxis to acquire robotic PCI company Robocath for up to $45M

FDA links weight loss pill to ‘unexpected’ cardiovascular risks

EHRA 2026

PFA associated with heightened stroke risk